Secarna Pharmaceuticals “Secarna” is the leading independent European antisense drug discovery company with multiple innovative antisense therapies in various stages of pre-clinical development in the areas of oncology/immuno-oncology, immunology, as well as inflammatory, fibrotic, neurodegenerative and cardiometabolic diseases. Founded in 2015 by an experienced management team, we are now proud to have established our discovery and development unit with more than 2,000 square feet of lab and office space at the IZB Martinsried – one of Germany’s most vibrant biotechnology clusters.
Our unique platform, LNAplus™
Our proprietary 3rd generation antisense oligonucleotide (ASO) platform, LNAplus™, encompasses all aspects of drug discovery and pre-clinical development and enables us to discover novel antisense-based therapies for challenging or currently undruggable targets. LNAplus™ as well as our ASOs identified by this platform have previously been validated by numerous in-house projects and in several academic and industry collaborations.
We want to maximize the performance and output of our LNAplus™ drug discovery platform and develop highly specific, safe and efficacious antisense therapies for indications in which antisense-based approaches have clear benefits compared to other therapeutic modalities.